After applying the inclusion and exclusion criteria, the eligible population included 3,535 patients with breast cancer, lung cancer, NHL, ovarian cancer, or colorectal cancer receiving G-CSF prophylaxis. The gene discussed is CSF3; the disease is lung carcinoma.